• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Paclitaxel"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 88

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience 

      Pectasides, Dimitrios; Fountzilas, George; Aravantinos, Gerasimos; Kalofonos, H. P.; Efstathiou, E.; Farmakis, D.; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Economopoulos, T.; Dimopoulos, M. A. (2006)
      Purpose.: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC). This study ...

    • Article  

      Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: Pilot study of an effective subtoxic therapy 

      Karavasilis, V.; Briassoulis, E. Ch; Siarabi, O.; Pavlidis, Nicholas (2003)
      Taxane-based chemotherapy has shown activity but also toxicity when administered at standard doses in patients with hormone-resistant prostate cancer (HRPC). In this pilot study, we investigated biweekly low-dose docetaxel ...

    • Article  

      Can circulated lung cancer cells pass to the urine without apparent urine tract metastases?. A single centre series 

      Kamposioras, K.; Pentheroudakis, George; Malamou-Mitsi, Vassiliki D.; Pappa, L.; Bafa, M.; Pavlidis, Nicholas (2008)
      Urine cytology has been a useful tool for the diagnosis of urinary tract malignancies. However, the presence of tumor cells in the urine sediment without an obvious urothelial metastatic deposit is a rare phenomenon and ...

    • Article  

      Cancer and pregnancy: A comprehensive review 

      Voulgaris, E.; Pentheroudakis, George; Pavlidis, Nicholas (2011)
      Background: Pregnancy complicated by cancer is relatively rare but, as women in western societies tend to delay childbearing to the third and fourth decade of life, this phenomenon is going to be encountered more often in ...

    • Article  

      Cancer of unknown primary (CUP) 

      Pavlidis, Nicholas; Fizazi, K. (2005)
      Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...

    • Article  

      Cancer of unknown primary origin 

      Briassoulis, E. Ch; Pavlidis, Nicholas (1997)
      About 3 % of all cancer patients suffer from cancer of unknown primary origin. These patients present with metastatic disease for which a primary site cannot be detected at the time of diagnosis. Sophisticated diagnostic ...

    • Article  

      Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer 

      Economopoulou, P.; Mountzios, G.; Pavlidis, Nicholas; Pentheroudakis, George (2015)
      Cancer of Unknown Primary (CUP) comprises a heterogeneous disease group with diagnosis of metastatic malignancy in the absence of an identifiable primary site after diagnostic work up. CUP may either resemble a specific ...

    • Article  

      Cancer of unknown primary site 

      Pavlidis, Nicholas; Pentheroudakis, George (2012)
      Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5 of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease with early dissemination. ...

    • Article  

      Cancer of unknown primary site: 20 questions to be answered 

      Pavlidis, Nicholas; Pentheroudakis, George (2010)
      Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic ...

    • Article  

      Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 

      Peccatori, Fedro A.; Azim, Hatem A.; Orecchia, R.; Hoekstra, H. J.; Pavlidis, Nicholas; Kesic, V.; Pentheroudakis, George (2013)

    • Article  

      Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 

      Fizazi, K.; Greco, F. A.; Pavlidis, Nicholas; Pentheroudakis, George (2011)

    • Article  

      Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 

      Pavlidis, Nicholas; Briassoulis, E. Ch; Pentheroudakis, George (2010)

    • Article  

      Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study 

      Briassoulis, E. Ch; Kalofonos, H. P.; Bafaloukos, Dimitrios; Samantas, E.; Fountzilas, George; Xiros, N.; Skarlos, Dimosthenis V.; Christodoulou, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)
      Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...

    • Article  

      Carcinoma of unknown primary (CUP) 

      Pavlidis, Nicholas; Fizazi, K. (2009)
      Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...

    • Article  

      Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support 

      Briassoulis, E. Ch; Froudarakis, M. E.; Milionis, Haralampos J.; Peponis, I. A.; Constantopoulos, S. H.; Pavlidis, Nicholas (2000)
      Several cancer therapeutic agents have been associated with pulmonary toxicity. Herein, we describe the case of a 73-year-old woman with breast cancer metastatic to the liver, who developed noncardiogenic pulmonary edema ...

    • Article  

      Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study 

      Kosmidis, Paraskevas A.; Fountzilas, George; Baka, S.; Samantas, E.; Dimopoulos, M. A.; Gogas, H.; Skarlos, Dimosthenis V.; Papacostas, P.; Boukovinas, I.; Bakoyiannis, Chris; Pantelakos, P.; Athanassiou, E.; Misailidou, D.; Tsekeris, P.; Pavlidis, Nicholas (2007)
      Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent ...

    • Article  

      Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results 

      Kosmidis, Paraskevas A.; Mylonakis, N.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Samantas, E.; Dimitriadis, K.; Kalofonos, H. P.; Tsavdaridis, D.; Skarlos, Dimosthenis V. (2000)
      Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...

    • Article  

      Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis 

      Golfinopoulos, Vassilis; Pentheroudakis, George; Salanti, G.; Nearchou, A. D.; Ioannidis, J. P. A.; Pavlidis, Nicholas (2009)
      Objectives: To synthesize the evidence from randomized controlled trials concerning systemic treatment regimens for patients with cancer of unknown primary site (CUP). Data sources: PubMed and the Cochrane Library Central ...

    • Article  

      Diagnostic and therapeutic management of cancer of an unknown primary 

      Pavlidis, Nicholas; Briassoulis, E. Ch; Hainsworth, J.; Greco, F. A. (2003)
      Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all malignant neoplasms and is therefore one of the 10 most frequent cancer diagnoses in man. Patients with CUP present with metastatic disease ...

    • Article  

      Docetaxel (Taxotere™) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG) 

      Cerny, T.; Kaplan, S.; Pavlidis, Nicholas; Schöffski, P.; Epelbaum, R.; Meerbeek, J. van; Wanders, J.; Franklin, H. R.; Kaye, Stanley B. (1994)
      In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD